Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, Austrian Post (18/12/2023)

24.12.2023

Marinomed: Marinomed Biotech AG considers strategic options for its Carragelose business and has mandated an external advisor. A structured process was initiated, in which Marinomed and the advisor will start engaging with potential partners. This initiative meets an attractive market environment for those assets that comply with the new EU medical device regulation (MDR). In May 2024, an important interim period ends imposing challenging requirements for all medical devices. Products that don’t fulfil these requirements lose their certificate and must not be marketed. Carragelose products fulfil all necessary prerequisites for the MDR and are backed by extensive clinical data, comprising >1000 patients in 12 international clinical trials. Carragelose is a unique, patent-protected, broadly active virus-blocking compound and is currently used in a marketed product portfolio for the prophylaxis and treatment of viral respiratory infections. Recent clinical data also support the extension of using Carragelose in Allergy and Eye Care, while the potential of further applications is not yet fully exploited. “MDR-ready products receive a lot of interest from OTC-focused companies. Carragelose products are MDR-ready, which underpins that the time for starting a structured process is right now. It may also become an option in our effort to support the financial stability and flexibility of Marinomed. At the same time, the negotiations for restructuring the debt with the EIB are on the right track. We are still driven by our goal to become profitable in 2024,” Pascal Schmidt, CFO of Marinomed, says. Marinomed Biotech: weekly performance: -4.00%

Austrian Post: The Supervisory Board of Austrian Post appointed Walter Oblin as Chairman of the Management Board and CEO of Austrian Post. The appointment takes effect on 1 October 2024. Walter Oblin has been with the company since 1 October 2009 and has been Chief Financial Officer of Austrian Post since 1 July 2012. On 1 January 2019, he was appointed Deputy Chief Executive Officer and, in addition to his role as Management Board Member responsible for Finance, also took on responsibility for the Mail Division. Walter Oblin will continue in his current role as Management Board Member responsible for Finance and Mail (CFO) until he takes over the position of the Chairman of the Management Board.
Österreichische Post: weekly performance: 2.66%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (18/12/2023)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, Austrian Post (18/12/2023)


24.12.2023, 2504 Zeichen



Marinomed: Marinomed Biotech AG considers strategic options for its Carragelose business and has mandated an external advisor. A structured process was initiated, in which Marinomed and the advisor will start engaging with potential partners. This initiative meets an attractive market environment for those assets that comply with the new EU medical device regulation (MDR). In May 2024, an important interim period ends imposing challenging requirements for all medical devices. Products that don’t fulfil these requirements lose their certificate and must not be marketed. Carragelose products fulfil all necessary prerequisites for the MDR and are backed by extensive clinical data, comprising >1000 patients in 12 international clinical trials. Carragelose is a unique, patent-protected, broadly active virus-blocking compound and is currently used in a marketed product portfolio for the prophylaxis and treatment of viral respiratory infections. Recent clinical data also support the extension of using Carragelose in Allergy and Eye Care, while the potential of further applications is not yet fully exploited. “MDR-ready products receive a lot of interest from OTC-focused companies. Carragelose products are MDR-ready, which underpins that the time for starting a structured process is right now. It may also become an option in our effort to support the financial stability and flexibility of Marinomed. At the same time, the negotiations for restructuring the debt with the EIB are on the right track. We are still driven by our goal to become profitable in 2024,” Pascal Schmidt, CFO of Marinomed, says. Marinomed Biotech: weekly performance: -4.00%

Austrian Post: The Supervisory Board of Austrian Post appointed Walter Oblin as Chairman of the Management Board and CEO of Austrian Post. The appointment takes effect on 1 October 2024. Walter Oblin has been with the company since 1 October 2009 and has been Chief Financial Officer of Austrian Post since 1 July 2012. On 1 January 2019, he was appointed Deputy Chief Executive Officer and, in addition to his role as Management Board Member responsible for Finance, also took on responsibility for the Mail Division. Walter Oblin will continue in his current role as Management Board Member responsible for Finance and Mail (CFO) until he takes over the position of the Chairman of the Management Board.
Österreichische Post: weekly performance: 2.66%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (18/12/2023)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

SportWoche ÖTV-Spitzentennis Podcast: Maximale Zwischenwoche mit starkem Sandro Kopp, man darf auch auf die Fussball-WM schauen




 

Bildnachweis

Aktien auf dem Radar:AT&S, DO&CO, Polytec Group, Austriacard Holdings AG, Amag, Kapsch TrafficCom, Bawag, Lenzing, ATX, ATX Prime, ATX TR, ATX NTR, Erste Group, CPI Europe AG, Mayr-Melnhof, RBI, Fabasoft, Verbund, EuroTeleSites AG, Frauenthal, Frequentis, Linz Textil Holding, Marinomed Biotech, Rosenbauer, VIG, Zumtobel, BTV AG, BKS Bank Stamm, Österreichische Post, Telekom Austria.


Random Partner

Kontron
Der Technologiekonzern Kontron AG – ehemals S&T AG – ist mit mehr als 6.000 Mitarbeitern und Niederlassungen in 32 Ländern weltweit präsent. Das im SDAX® an der Deutschen Börse gelistete Unternehmen ist einer der führenden Anbieter von IoT (Internet of Things) Technologien. In diesen Bereichen konzentriert sich Kontron auf die Entwicklung sicherer und vernetzter Lösungen durch ein kombiniertes Portfolio aus Hardware, Software und Services.

>> Besuchen Sie 55 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten